Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy.
Paweł
P
Rubiś
Sylwia
S
Wiśniowska-Śmiałek
Katarzyna
K
Holcman
Agata
A
Leśniak-Sobelga
Magdalena
M
Kostkiewicz
Piotr
P
Podolec
D000613:Aminobutyrates / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001713:Biphenyl Compounds; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy*; D004338:Drug Combinations; D004656:Enalapril / Q000494:pharmacology; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors; D061214:Patient Safety; D013777:Tetrazoles / Q000494:pharmacology; D016896:Treatment Outcome; D000068756:Valsartan / Q000494:pharmacology
D000613:Aminobutyrates; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D004656:Enalapril; D000068756:Valsartan; D015260:Neprilysin; C549068:sacubitril and valsartan sodium hydrate drug combination